What was the price range for the reported CPIX share purchases?

Reported purchase prices ranged from $3.14 to $3.63 .

[Form 4] CUMBERLAND PHARMACEUTICALS INC Insider Trading Activity

Q: How many CPIX shares were acquired in each transaction?

Each reported transaction reflects the acquisition of 6 shares .

Q: Over what dates did the CPIX insider transactions occur?

Transactions occurred on trading days from October 1 through October 31, 2025 .

Q: What is the reporting person’s relationship to CPIX?

The reporting person is a Director of Cumberland Pharmaceuticals.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Cumberland Pharmaceuticals (CPIX) — insider share acquisitions reported. Director Caroline Young disclosed a series of automatic purchases executed under a Rule 10b5-1 trading plan.

The filing lists acquisitions of 6 shares on multiple trading days from October 1–31, 2025, at prices ranging from $3.14 to $3.63. Following the final reported transaction on October 31, 2025, the director beneficially owned 33,168 shares, held directly. The transactions were made pursuant to a 10b5-1 plan adopted on November 14, 2024.

Insider Trade Summary

23 transactions reported

Mixed 23 txns

Insider Young Caroline

Role Director

Type	Security	Shares	Price	Value
L	Common Stock	6	$3.39	$20.34
L	Common Stock	6	$3.29	$19.74
L	Common Stock	6	$3.26	$19.56
L	Common Stock	6	$3.28	$19.68
L	Common Stock	6	$3.49	$20.94
L	Common Stock	6	$3.51	$21.06
L	Common Stock	6	$3.44	$20.64
L	Common Stock	6	$3.62	$21.72
L	Common Stock	6	$3.61	$21.66
L	Common Stock	6	$3.52	$21.12
L	Common Stock	6	$3.48	$20.88
L	Common Stock	6	$3.49	$20.94
L	Common Stock	6	$3.37	$20.22
L	Common Stock	6	$3.35	$20.10
L	Common Stock	6	$3.54	$21.24
L	Common Stock	6	$3.59	$21.54
L	Common Stock	6	$3.56	$21.36
L	Common Stock	6	$3.63	$21.78
L	Common Stock	6	$3.19	$19.14
L	Common Stock	6	$3.14	$18.84
L	Common Stock	6	$3.25	$19.50
L	Common Stock	6	$3.28	$19.68
L	Common Stock	6	$3.31	$19.86

Holdings After Transaction: Common Stock — 33,168 shares (Direct)

Footnotes (1)

[object Object]

Form 4 Insider Transactions: What Each Field Means →

11/03/2025 - 07:59 AM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Young Caroline

(Last)

(First)

(Middle)

1600 WEST END AVENUE

SUITE 1300

(Street)

NASHVILLE

37203

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
CUMBERLAND PHARMACEUTICALS INC [ CPIX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
10/01/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	10/01/2025		L	V	6⁽¹⁾	A	$3.31	33,036	D
Common Stock	10/02/2025		L	V	6⁽¹⁾	A	$3.28	33,042	D
Common Stock	10/03/2025		L	V	6⁽¹⁾	A	$3.25	33,048	D
Common Stock	10/06/2025		L	V	6⁽¹⁾	A	$3.14	33,054	D
Common Stock	10/07/2025		L	V	6⁽¹⁾	A	$3.19	33,060	D
Common Stock	10/08/2025		L	V	6⁽¹⁾	A	$3.63	33,066	D
Common Stock	10/09/2025		L	V	6⁽¹⁾	A	$3.56	33,072	D
Common Stock	10/10/2025		L	V	6⁽¹⁾	A	$3.59	33,078	D
Common Stock	10/13/2025		L	V	6⁽¹⁾	A	$3.54	33,084	D
Common Stock	10/14/2025		L	V	6⁽¹⁾	A	$3.35	33,090	D
Common Stock	10/15/2025		L	V	6⁽¹⁾	A	$3.37	33,096	D
Common Stock	10/16/2025		L	V	6⁽¹⁾	A	$3.49	33,102	D
Common Stock	10/17/2025		L	V	6⁽¹⁾	A	$3.48	33,108	D
Common Stock	10/20/2025		L	V	6⁽¹⁾	A	$3.52	33,114	D
Common Stock	10/21/2025		L	V	6⁽¹⁾	A	$3.61	33,120	D
Common Stock	10/22/2025		L	V	6⁽¹⁾	A	$3.62	33,126	D
Common Stock	10/23/2025		L	V	6⁽¹⁾	A	$3.44	33,132	D
Common Stock	10/24/2025		L	V	6⁽¹⁾	A	$3.51	33,138	D
Common Stock	10/27/2025		L	V	6⁽¹⁾	A	$3.49	33,144	D
Common Stock	10/28/2025		L	V	6⁽¹⁾	A	$3.28	33,150	D
Common Stock	10/29/2025		L	V	6⁽¹⁾	A	$3.26	33,156	D
Common Stock	10/30/2025		L	V	6⁽¹⁾	A	$3.29	33,162	D
Common Stock	10/31/2025		L	V	6⁽¹⁾	A	$3.39	33,168	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. The reported purchase occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 14, 2024.

Remarks:

	Caroline Young by /s/ John Hamm as attorney-in-fact	11/03/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What did Cumberland Pharmaceuticals (CPIX) disclose in this Form 4?

A director reported automatic purchases of common stock under a Rule 10b5-1 trading plan.

How many CPIX shares were acquired in each transaction?

Each reported transaction reflects the acquisition of 6 shares.

What is the total beneficial ownership after the last transaction?

Following the October 31, 2025 transaction, the director beneficially owned 33,168 shares, held directly.

Over what dates did the CPIX insider transactions occur?

Transactions occurred on trading days from October 1 through October 31, 2025.

Was a Rule 10b5-1 trading plan used for these transactions?

Yes. The purchases occurred automatically under a Rule 10b5-1 plan adopted on November 14, 2024.

What is the reporting person’s relationship to CPIX?

The reporting person is a Director of Cumberland Pharmaceuticals.